The Lancet 403(10437):16351648 Kosiborod MN, Abildstrm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity
Tirzepatide was also associated with greater reductions in waist circumference and higher rates of achieving at least 25% weight loss
Much more research is needed to uncover the potential benefits, as well as risks, of these medications
Acknowledgements We would like to thank Honyaku Center Inc
This product is supplied strictly as a research compound formulation and is not intended for human or veterinary use
It works by mimicking a hormone called GLP-1, which stimulates insulin production and reduces glucose in the bloodstream